The pharmacogenetics of coumarin therapy.
The pharmacogenetics of coumarin therapy.
复制标题
DOI：
10.2217/14622416.6.5.503
复制
发表时间：
2005-11
期刊：
影响因子：
2.1
通讯作者：
D. Voora;H. McLeod;C. Eby;B. Gage
中科院分区：
文献类型：
--
作者：
D. Voora;H. McLeod;C. Eby;B. Gage
维生素K拮抗剂（香豆素）是广泛使用的口服抗凝剂，用于预防静脉血栓栓塞和中风。剂量反应的广泛个体间差异和频繁出血是香豆素治疗开始的特征。在过去的10年里，香豆素剂量反应的遗传和非遗传决定因素已经被确定。华法林起始治疗的综合药物遗传学方法有可能提高华法林起始治疗的安全性和有效性。
Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumarin dose response have been identified. A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation.